Wellington Shields Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.55M Hold
45,773
– – 0.2% 91
2026
Q1
$1.38M Hold
45,773
– – 0.21% 88
2025
Q4
$1.43M Hold
45,773
– – 0.21% 86
2025
Q3
$925K Sell
45,773
-1,927
-4% -$33.8K 0.14% 116
2025
Q2
$799K Sell
47,700
-800
-2% -$12.9K 0.14% 118
2025
Q1
$745K Buy
+48,500
New +$866K 0.14% 112
2013
Q4
– Sell
-8,152
Closed -$308K – 336
2013
Q3
$308K Sell
8,152
-704
-8% -$27.5K 0.06% 235
2013
Q2
$347K Buy
+8,856
New +$345K 0.06% 237

Other funds holding TEVA

Wellington Shields Capital Management's TEVA Position: Q2 2026 in Review

Wellington Shields Capital Management held its Teva Pharmaceutical Industries Limited (TEVA) position steady in Q2 2026 at 45,773 shares worth $1.55M. The position accounts for 0.2% of the portfolio, ranked #91.

Wellington Shields Capital Management first reported a position in TEVA in Q2 2013 and has held it in 8 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Wellington Shields Capital Management held 45,773 shares of Teva Pharmaceutical Industries Limited worth $1.55M as of Q2 2026.
  • Wellington Shields Capital Management left its Teva Pharmaceutical Industries Limited share count unchanged in Q2 2026.
  • Teva Pharmaceutical Industries Limited made up 0.2% of Wellington Shields Capital Management's portfolio in Q2 2026, its #91 holding.
  • Wellington Shields Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and has held it in 8 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Wellington Shields Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.